Inflammatory Bowel Diseases

PCR-Restriction fragment length polymorphism

PCR-RFLP

Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease

Three single nucleotide polymorphisms in the lymphoid tyrosine phosphatase gene(SNP (G788>A) in exon10, SNP (C1858>T) in exon 14 and SNP (G -1123>C) in the promoter region ) will be assessed in 100 patients diagnosed as inflammatory bowel disease and 100 healthy subjects by Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) to detect association between these polymorphisms and inflammatory bowel disease

Serum Erythrocyte Sedimentation Rate ,C-Reactive Protien ,Anti Nuclear Antibody ,Antineutrophil Cytoplasmic Antibody (ANCA) and Anti Saccharomyces Cerevisiae (ASCA) and fecal calprotectin will be done to all patients.The three investigated polymorphisms in LYP will be correlated with the markers of disease activity and IBD patients response to therapy.

Mennat-Allah Refaat Ali

doctor

Assiut University

Subjects with no prior therapy:
Pembrolizumab administered at 200 mg
Paclitaxel administered at 175mg/m2
Carboplatin administered at an AUC of 6
Subjects with prior external beam radiation therapy (XRT) and/or platinum-based chemotherapy must initiate paclitaxel and carboplatin at a reduced dose:
Pembrolizumab administered at 200 mg
Paclitaxel administered at 135mg/m2
Carboplatin administered at an AUC of 5

Endometrial Cancer

Endometrial Adenocarcinoma

Pembrolizumab 200 mg will be administered every 3 weeks for all subjects

Pembrolizumab

For subjects with no prior therapy, paclitaxel will be dosed at 175mg/m2 and be administered as a 3-hour continuous IV infusion.
Subjects with prior XRT/platinum-based chemotherapy must initiate paclitaxel at 135mg/m2 and be administered as a 3-hour continuous IV infusion.

Paclitaxel

For subjects with no prior therapy, carboplatin will be dosed at an AUC of 6 and given as an IV infusion in 250ml of D5W over 30 minutes.
Subjects with prior XRT/platinum-based chemotherapy must initiate carboplatin at an AUC of 5 given as an IV infusion in 250ml of D5W over 30 minutes.

Carboplatin

Big Ten Cancer Research Consortium Website

Ironwood Cancer and Research Centers

Northwestern University, Robert H. Lurie Cancer Center

Northwestern Medicine Lake Forest Hospital

Indiana University Melvin and Bren Simon Cancer Center

University of Iowa Hospitals and Clinics

University of Minnesota

Pembro/Carbo/Taxol in Endometrial Cancer

Phase II Study of Pembrolizumab in Combination With Carboplatin and Paclitaxel for Advanced or Recurrent Endometrial Adenocarcinoma

Proportion of confirmed partial response (PR) and complete response (CR) rates per Response Evaluation Criteria In Solid Tumors (RECIST 1.1) criteria for evaluable subjects receiving pembrolizumab in combination with standard carboplatin/paclitaxel therapy.

Proportion of subjects who experience ≥ Grade 3 toxicity according per Common Toxicity Criteria for Adverse Effects (CTCAE) v4 criteria while receiving pembrolizumab in combination with standard carboplatin/paclitaxel therapy

Daniela Matei, MD

Sponsor-Investigator

Merck Sharp & Dohme Corp.

Hoosier Cancer Research Network

flecainide x 6 months, then crossover to sotalol x 6 months

sotalol x 6 months, then crossover to flecainide x 6 months

Atrial Fibrillation

flecainide up to 150mg twice daily for the control of atrial fibrillation

Flecainide

sotalol up to 120mg twice daily for the control of atrial fibrillation

Sotalol

Jesse Brown VA Medical Center

Rush University Medical Center

University of Illinois at Chicago

Advocate Christ Medical Center

Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation

A Prospective, Multi-Center, Randomized, Open Label Trial to Determine if a Common Atrial Fibrillation Risk Locus Modulates Differential Response to Antiarrhythmic Drugs

Subjects will be monitored with the Medtronic Reveal LINQ Insertable Cardiac Monitor (ICM) system to assess AF burden. The device will be programmed to optimize the memory for storing AF episode..

Quality of life assessment: Patients will be asked to fill out the AFEQT quality of life questionnaire baseline (study randomization), two, four, six, eight, ten, and 12 months (completion of the study). The questionnaire at the end of the 6rd month will be administered just prior to stopping the first study drug. The validated questionnaire is comprised of 20 questions about AF symptoms with answers given on a Likert scale. The questionnaire will be provided to the patients in paper format either in person or by mail, as applicable. A follow-up phone call will be made to each patient to ensure that the questionnaire is completed and returned.

Dawood Darbar, MD

Professor of Medicine

Medtronic

Hypercholesterolemia

3,5-Diiodothyropropionic acid (DITPA) therapy

Johns Hopkins Bayview Medical Center

Study of 3,5-Diiodothyropropionic Acid (DITPA) in Hypercholesterolemic Patients

A Randomized, Double-Blind Placebo-Controlled Study of 3,5-diiodothyropropionic Acid (DITPA) in Combination With Standard Therapy to Attain NCEP ATP III Goal for LDL Cholesterol in Hypercholesterolemic Patients

alopecia/phosphatase

Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease

Pembro/Carbo/Taxol in Endometrial Cancer

Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation

Study of 3,5-Diiodothyropropionic Acid (DITPA) in Hypercholesterolemic Patients

Najbardziej kompletna baza danych ziół leczniczych poparta naukowo